探讨瑞舒伐他汀和阿托伐他汀治疗冠心病的临床疗效

目的 分析瑞舒伐他汀和阿托伐他汀治疗冠心病的临床疗效和安全性.方法 选取收治的50例冠心病患者作为观察组,并将同期收治的50例冠心病患者设为对照组,予以对照组阿托伐他汀治疗,观察组患者给予服用瑞舒伐他汀,对两组患者的临床效果以及安全性进行评价.结果 观察组和对照组总有效率分别为98%、70%,存在明显差异,有统计学意义(P<0.05).观察组患者治疗后的LDL-C、TG、TC、hs-CRP、LVEF、HDL-C及FMD相比于对照组来说有明显的改善,存在明显的差异性和统计学意义(P<0.05).观察组和对照组患者发生不良反应的几率分别为6%、30%,存在明显差异,有统计学意义(P<0.05).结论 冠心病患者采取瑞舒伐他汀治疗,疗效优于阿托伐他汀,安全性更高.     

匹伐他汀对早发冠心病急性心肌梗死患者血脂、空腹血糖的影响

目的探讨匹伐他汀与阿托伐他汀对早发冠心病急性心肌梗死患者血脂及空腹血糖(FBG)的影响。方法选取锦州医科大学附属第一医院心内科2018年8月-2019年4月收治的早发冠心病急性心肌梗死患者146例,随机均分成匹伐他汀组(匹伐他汀钙分散片,2 mg/d)和阿托伐他汀组(阿托伐他汀钙胶囊,20 mg/d),每组73例,均持续治疗3个月。观察并比较两组治疗前及治疗后1、3个月的总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白(HDL)、低密度脂蛋白(LDL)及FBG水平。结果治疗前两组的TC、TG、HDL、LDL比较差异无统计学意义(P>0.05)。治疗1、3个月后,匹伐他汀组患者的TC低于治疗前[(3.80±0.78) mmol/L、(3.78±0.76) mmol/L vs.(4.55±1.12) mmol/L]、TG低于治疗前[(1.41±0.56) mmol/L、(1.21±0.42) mmol/L vs.(1.85±1.05) mmol/L]、LDL低于治疗前[(2.21±0.75) mmol/L、2.18±0.67) mmol/L vs.(2.97±0.81) mmol/L...     

瑞舒伐他汀与阿托伐他汀治疗冠心病的效果对比研究

目的：分析冠心病患者行瑞舒伐他汀、阿托伐他汀疗法的效果。方法120例冠心病患者随机抽选,抽样分组处理后实施不同疗法：阿托伐他汀疗法对照组,瑞舒伐他汀疗法试验组,评定治疗结束后的效果。结果试验组患者的疾病效果高于对照组,不良发应率低于对照组, P＜0.05,统计有区别。结论临床给予冠心病患者瑞舒伐他汀疗法作用突出,可改善心功能,增强疗效,值得借鉴。     

瑞舒伐他汀辅助治疗冠心病伴高脂血症疗效观察

目的:观察瑞舒伐他汀辅助治疗冠心病伴高脂血症的临床疗效及安全性。方法:选取某医院2017年1月-2018年12月收治的冠心病伴高脂血症60例,随机分为对照组和观察组各30例。对照组口服阿托伐他汀钙片治疗,观察组口服瑞舒伐他汀钙片治疗,两组均持续治疗6个月。比较两组临床疗效,以及血清总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、载脂蛋白A1(ApoA1)、载脂蛋白B(ApoB)、超敏C反应蛋白(hs-CRP)和血尿素氮(BUN)、丙氨酸氨基转移酶(ALT)、肌酸激酶(CK)、血肌酸酐(SCr)等水平。结果:观察组治疗总有效率为93.33%,显著高于对照组的73.33%(P<0.05)。治疗后,观察组血清TC、TG、LDL-C、ApoA1、ApoB和hs-CRP等水平均非常显著低于对照组(P<0.01),HDL-C水平非常显著高于对照组(P<0.01);两组血清BUN、ALT、CK和SCr水平比较,差异不显著(P>0.05)。两组均未发生药物相关不良反应。结论:瑞舒伐他汀治疗冠心病伴高脂血症临床疗效优于阿托伐...     

阿托伐他汀对2型糖尿病患者外周血单核细胞TLR4表达的影响

目的探讨阿托伐他汀对2型糖尿病的抗炎作用机制是否与抑制toll样受体4(TLR4)有关。方法将40例2型糖尿病患者随机分为常规治疗组和阿托伐他汀治疗组。阿托伐他汀治疗组患者在常规治疗基础上给予阿托伐他汀20 mg,1次/d,晚间口服。治疗前及治疗1月后采血,应用流式细胞仪检测外周血单核细胞TLR4蛋白表达;应用酶联免疫(ELISA)法检测血浆肿瘤坏死因子-α(TNF-α)浓度。结果单核细胞TLR4蛋白与血糖,糖化血红蛋白及血浆TNF-α呈正相关。治疗1月后,阿托伐他汀治疗组和常规治疗组血糖、外周血单核细胞TLR4蛋白及血浆TNF-α浓度均较治疗前降低(P<0.05);阿托伐他汀治疗组单核细胞TLR4蛋白和血浆TNF-α均低于常规治疗组(P<0.05)。结论阿托伐他汀能下调2型糖尿病患者的单核细胞TLR4表达,降低血浆炎症因子水平。其抗炎作用可能与抑制单核细胞TLR4通路有关。     

不同剂量阿托伐他汀治疗冠心病患者疗效观察

目的探讨不同剂量阿托伐他汀治疗冠心病患者的临床疗效。方法选取自2013年1月至2017年12月北部战区空军医院心内科收治的361例冠心病患者为研究对象。采用随机数字表法将其分为A组(n=181)与B组(n=180)。在常规治疗的基础上,A组患者行阿托伐他汀片20 mg/d治疗,B组患者行阿托伐他汀片40 mg/d治疗。比较两组患者治疗前后的血脂水平、肝功能指标水平、肾功能指标水平及治疗后的低密度脂蛋白胆固醇(LDL-C)达标率。结果治疗后,两组患者的血脂水平较治疗前均下降,但差异无统计学意义(P>0.05)。治疗后,两组患者肝功能、肾功能指标比较,差异均无统计学意义(P>0.05)。治疗后,两组患者的LDL-C达标率较治疗前均升高,且B组升高更为显著;各组治疗前后LDL-C达标率比较,差异均有统计学意义(P<0.05)。结论高剂量与常规剂量的阿托伐他汀均对冠心病患者有降脂疗效,对于血脂不达标的患者,高剂量阿托伐他汀对LDL-C达标率提高得更为显著,对患者的肝肾功能无显著影响,且安全性良好。     

氟伐他汀对急性冠脉综合征血清高敏C反应蛋白影响研究

目的:观察氟伐他汀对急性冠脉综合征(ACS)血清高敏C反应蛋白(Hs-CRP)水平的影响。方法:ACS132例随机分为观察组67例和对照组65例。对照组采用常规治疗,观察组在常规治疗基础上加用氟伐他汀(40mg/天),分别测定两组在治疗前与治疗后1周、2周、1个月及3个月时的Hs-CRP水平。结果:观察组在治疗1个月时Hs-CRP水平开始下降,至3个月时进一步降低;而对照组在治疗3个月时Hs-CRP水平才开始下降。观察组治疗1个月和3个月时Hs-CRP水平显著低于同期对照组(P<0.05)。结论:氟伐他汀可以明显降低ACS患者血清中Hs-CRP水平。     

瑞舒伐他汀联合黄芪多糖治疗冠心病临床效果观察

目的观察瑞舒伐他汀联合黄芪多糖治疗冠心病的临床效果。方法选取西安市第五医院自2014年2月至2018年10月收治的90例冠心病患者为研究对象。将患者随机分入A组和B组,每组各45例。A组患者接受常规治疗及瑞舒伐他汀,B组患者在A组基础上联合黄芪多糖治疗。比较两组患者的治疗有效率、治疗前后血脂指标变化及不良反应发生情况。结果 B组有效率(95.6%)明显高于A组(82.2%),差异有统计学意义(P<0.05)。治疗后,两组患者总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平均较治疗前下降,且B组低于A组,差异有统计学意义(P<0.05);B组高密度脂蛋白胆固醇水平较治疗前升高,且高于A组,差异有统计学意义(P<0.05)。治疗期间,A组、B组不良反应发生率分别为6.7%(3/45)、8.9%(4/45),差异无统计学意义(P>0.05)。结论瑞舒伐他汀联合黄芪多糖治疗冠心病安全有效,可有效改善血脂指标。     

瑞舒伐他汀钙对冠心病患者血脂及颈动脉粥样硬化斑块的影响研究

目的探讨瑞舒伐他汀钙对冠心病患者血脂水平及颈动脉粥样硬化斑块的影响。方法 42例冠心病合并颈动脉粥样硬化斑块的患者给予口服瑞舒伐他汀钙片,10 mg/d,疗程12个月,测定患者治疗前及治疗6、12个月时血浆总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)水平,彩色多普勒超声测定颈动脉内膜中层厚度(IMT)及计算颈动脉斑块积分。结果治疗6个月时,患者TC、TG及LDL-C水平与治疗前比较明显下降,而HDL-C水平明显升高,差异均有统计学意义(P<0.05),治疗12个月后,与治疗6个月时比较差异有统计学意义(P<0.05);治疗6个月时颈动脉IMT与治疗前比较显著减轻,颈动脉粥样斑块积分明显下降,差异有统计学意义(P<0.05),治疗12个月时与治疗6个月时比较差异有统计学意义(P<0.05)。结论冠心病患者口服瑞舒伐他汀钙可显著改善其血脂水平及动脉粥样硬化程度。     

阿托伐他汀对冠心病心力衰竭患者血管内皮功能的影响

目的 研究阿托伐他汀(立普妥)对冠心病(CHD)合并充血性心力衰竭(CHF)患者血浆中一氧化氮(NO)、降钙素基因相关肽(CGRP)和内皮素(ET)的影响.方法 将68例CHD并CHF患者分为2组,常规用药对照组(地高辛、氢氧噻嗪、硝酸异山梨酯)34例,常规用药加阿托伐他汀联用组34例,并设正常人组34例.N0测定用Greiss法,放射性免疫法测定治疗前后血中CGRP和ET的水平.结果 CHD并CHF患者中NO和CGRP水平明显低于正常人组(P<0.01),ET显著高于正常人组(P<0.01),治疗后均显著改善(P<0.01),且以常规用药加阿托伐他汀组改善更为显著,与常规组治疗后比较差异有统计学意义(P<0.05).结论 常规用药加阿托伐他汀能显著改善CHD合并CHF患者的NO、CGRP和ET的代谢失衡.     

Knee injury and Osteoarthritis Outcome Score (KOOS) - validation of a Swedish version

The Knee injury and Osteoarthritis Outcome Score (KOOS) is a self-administered instrument measuring outcome after knee injury at impairment, disability, and handicap level in five subscales. Reliability, validity, and responsiveness of a Swedish version was assessed in 142 patients who underwent arthroscopy because of injury to the menisci, anterior cruciate ligament, or cartilage of the knee. The clinimetric properties were found to be good and comparable to the American version of the KOOS. Comparison to the Short Form-36 and the Lysholm knee scoring scale revealed expected correlations and construct validity. Item by item, symptoms and functional limitations were compared between diagnostic groups. High responsiveness was found three months after arthroscopic partial meniscectomy for all subscales but Activities of Daily Living.     

Endovascular management of carotid-cavernous fistulas

Objective To investigate endovascular treatment of traumatic direct carotid-cavernous fistulas （CCF） and their complications such as pseudoaneurysms. Methods： Over a five-year period, 22 patients with traumatic direct CCFs were treated endovascularly in our institution. Thirteen patients were treated once with the result of CCF occluded, 8 twice and 1 three times. Treatment modalities included balloon occlusion of the CCF, sacrifice of the ipsilateral internal carotid artery with detachable balloon, coll embolization of the cavernous sinus and secondary pseudoaneurysms, and covered-stem management of the pseudoaneurysms. Results All the direct CCFs were successfully managed endovascularly. Four patients developed a pseudoaneurysm after the occlusion of the CCF with an incidence of pseudoaneurysm formation of 18.2% （4/22）. A total number of 8 patients experienced permanent occlusion of the ICA with a rate of ICA occlusion reaching 36.4% （8/22）. Followed up through telephone consultation from 6 months to 5 years, all did well with no recurrence of CCF symptoms and signs. Conclusion Traumatic direct CCFs can be successfully managed with endovascular means. The pseudoaneurysms secondary to the occlusion of the CCFs can be occluded with stent-assisted coiling and implantation of covered stents.     

The acutely limping child

Acute limping may be the result of multiple pathologies in children. The differential diagnosis varies based on the age of the child. Irrespective of age, the initial imaging work-up includes AP and frog leg radiographs of the pelvis and ultrasound; MRI may sometimes be helpful. In children less than 3 years, infections and trauma are most frequent. MRI is the imaging modality of choice when osteomyelitis is clinically suspected. Between the ages of 3 and 10 years, transient synovitis of the hip and Legg-Calvé-Perthes disease are main considerations but infection, inflammation and focal bony lesions are also considered. In children over 10 years, slipped capital femoral epiphysis also is considered.     

Do Balance Board Training Programs Reduce the Risk of Ankle Sprains in Athletes?

Introduction Ankle sprains are the most common musculo-skeletal injury that occurs in athletes,particularly in sports that require jumping and landing on one foot such as soccer,and basketball(1-4).These injuries often result in significant time loss from participation,long-term disability,and have a major impact on health care costs and resources(5-8).     

High Intensity Interval Training:New Insights

KEY POINTS ·High-intensity interval training(HIT)is characterized by repeated sessions of relatively brief，intermittent exercise.often performed with an“a11 out”effort or at an intensity close to that which elicits peak oxygen uptake(i.e.，≥90%of VO2 peak).     

Developmental validation of the PowerPlex(®) ESI 16 and PowerPlex(®) ESI 17 Systems: STR multiplexes for the new European standard

In response to the ENFSI and EDNAP groups’ call for new STR multiplexes for Europe, Promega^® developed a suite of four new DNA profiling kits. This paper describes the developmental validation study performed on the PowerPlex^® ESI 16 (European Standard Investigator 16) and the PowerPlex^® ESI 17 Systems. The PowerPlex^® ESI 16 System combines the 11 loci compatible with the UK National DNA Database^®, contained within the AmpFlSTR^® SGM Plus^® PCR Amplification Kit, with five additional loci: D2S441, D10S1248, D22S1045, D1S1656 and D12S391. The multiplex was designed to reduce the amplicon size of the loci found in the AmpFlSTR^® SGM Plus^® kit. This design facilitates increased robustness and amplification success for the loci used in the national DNA databases created in many countries, when analyzing degraded DNA samples. The PowerPlex^® ESI 17 System amplifies the same loci as the PowerPlex^® ESI 16 System, but with the addition of a primer pair for the SE33 locus. Tests were designed to address the developmental validation guidelines issued by the Scientific Working Group on DNA Analysis Methods (SWGDAM), and those of the DNA Advisory Board (DAB). Samples processed include DNA mixtures, PCR reactions spiked with inhibitors, a sensitivity series, and 306 United Kingdom donor samples to determine concordance with data generated with the AmpFlSTR^® SGM Plus^® kit. Allele frequencies from 242 white Caucasian samples collected in the United Kingdom are also presented. The PowerPlex^® ESI 16 and ESI 17 Systems are robust and sensitive tools, suitable for the analysis of forensic DNA samples. Full profiles were routinely observed with 62.5 pg of a fully heterozygous single source DNA template. This high level of sensitivity was found to impact on mixture analyses, where 54–86% of unique minor contributor alleles were routinely observed in a 1:19 mixture ratio. Improved sensitivity combined with the robustness afforded by smaller amplicons has substantially improved the quantity of data obtained from degraded samples, and the improved chemistry confers exceptional tolerance to high levels of laboratory prepared inhibitors.